🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Ifetroban Oral Capsule

    CUMBERLAND PHARMACEUTICALS INC

    Asthma, Aspirin-Induced

    phase 2 small molecule completed

    1 trial

  2. Ifetroban, Oral Capsule

    CUMBERLAND PHARMACEUTICALS INC

    Aspirin Exacerbated Respiratory Disease (AERD)

    phase 2 small molecule completed

    1 trial

  3. Iguratimod

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    ITP

    phase 2 small molecule active

    1 trial

  4. Imatinib

    The First People's Hospital of Lianyungang

    Progression-free Survival

    phase 2 small molecule active

    1 trial

  5. Immunization with P. vivax irradiated sporozoites

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  6. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  7. Immunomodulatory DC vaccines to target prostate cancer

    Shenzhen Second People's Hospital

    Prostate Cancer Indications

    phase 2 mab active

    1 trial

  8. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. Indigo naturalis ointment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Psoriasis

    phase 2 small molecule completed

    1 trial

  10. Induction Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

    phase 2 small molecule active

    1 trial

  11. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  12. Induction therapy of GP(Pomalidomide+Obinutuzumab）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  13. Inetetamab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  16. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  17. Injection of IAH0968+Gemcitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HER2 Gene Mutation

    phase 2 other active

    1 trial

  18. Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Acute

    phase 2 small molecule active

    1 trial

  19. Inotuzumab ozogamicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  20. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  21. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  22. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  24. Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Cell Carcinoma (RCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources